Prognostic value of exercise pulmonary haemodynamics in pulmonary arterial hypertension

European Respiratory Journal

Volumn 44, Issue 3, 2014, Pages 704-713

  Chaouat, Ari ^a,b   Sitbon, Olivier ^c,d   Mercy, Magalie ^a   Ponçot Mongars, Raphaëlle ^a   Steeve Provencher, Anne Guillaumot ^a,e   Gomez, Emmanuel ^a   Selton Suty, Christine ^a   Malvestio, Pascale ^a   Regent, Denis ^a   Paris, Christophe ^a,b   Hervé, Philippe ^f   Chabot, François ^a,b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c BICÊTRE HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e LAVAL UNIVERSITY   (Canada)

^f CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; PROSTACYCLIN; SILDENAFIL;

ADULT; AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; EXERCISE; FEMALE; HEART CATHETERIZATION; HEART INDEX; HEART RATE; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; WALKING; AREA UNDER THE CURVE; EXERCISE TEST; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FOLLOW UP; HEMODYNAMICS; HYPERTENSION, PULMONARY; MIDDLE AGED; PATHOPHYSIOLOGY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; AREA UNDER CURVE; CARDIAC CATHETERIZATION; EXERCISE; EXERCISE TEST; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; WALKING;

EID: 84906052227     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00153613     Document Type: Article

References (27)

1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl., D34-D41.
2. McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62: Suppl., D51-D59.
3. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
4. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007; 28: 1250-1257.
5. Haddad F, Doyle R, Murphy DJ, et al. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 2008; 117: 1717-1731.
6. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009; 120: 992-1007.
7. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl., D42-D50.
8. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
9. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
10. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
11. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
12. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
13. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
14. Castelain V, Chemla D, Humbert M, et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med 2002; 165: 338-340.
15. Blumberg FC, Riegger GA, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest 2002; 121: 1566-1571.
16. Chaouat A, Poncot-Mongars R, Sitbon O, et al. Impact of exercise pulmonary hemodynamic in idiopathic, heritable and anorexigen-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 185: A1887.
17. Provencher S, Hervé P, Sitbon O, et al. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur Respir J 2008; 32: 393-398.
18. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
19. Groepenhoff H, Holverda S, Marcus JT, et al. Stroke volume response during exercise measured by acetylene uptake and MRI. Physiol Meas 2007; 28: 1-11.
20. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-492.
21. Naeije R. The 6-min walk distance in pulmonary arterial hypertension: "Je t'aime, moi non plus". Chest 2010; 137: 1258-1260.
22. Provencher S, Chemla D, Hervé P, et al. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J 2006; 27: 114-120.
23. Galiè N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.
24. Mainguy V, Maltais F, Saey D, et al. Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax 2010; 65: 113-117.
25. Laveneziana P, Garcia G, Joureau B, et al. Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. Eur Respir J 2013; 41: 578-587.
26. Sun XG, Hansen JE, Oudiz RJ, et al. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001; 104: 429-435.
27. Grünig E, Tiede H, Enyimayew EO, et al. Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. Circulation 2013; 128: 2005-2015.